BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee HS, Cleynen I. Molecular Profiling of Inflammatory Bowel Disease: Is It Ready for Use in Clinical Decision-Making? Cells. 2019;8. [PMID: 31167397 DOI: 10.3390/cells8060535] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
Number Citing Articles
1 Ferguson LR. Inflammatory bowel disease: why this provides a useful example of the evolving science of nutrigenomics. Journal of the Royal Society of New Zealand 2020;50:299-315. [DOI: 10.1080/03036758.2020.1728345] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Park SH, Hwang SW, Ye BD, Noh S, Park JC, Kim JY, Kim J, Ham NS, Oh EH, Yang DH, Byeon JS, Myung SJ, Yang SK. Concordance regarding disease type and phenotypic characteristics among patients with familial inflammatory bowel disease. J Gastroenterol Hepatol 2020;35:988-93. [PMID: 31674059 DOI: 10.1111/jgh.14913] [Reference Citation Analysis]
3 Selin KA, Hedin CRH, Villablanca EJ. Immunological networks defining the heterogeneity of inflammatory bowel diseases. J Crohns Colitis 2021:jjab085. [PMID: 33959743 DOI: 10.1093/ecco-jcc/jjab085] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Valter M, Verstockt S, Finalet Ferreiro JA, Cleynen I. Extracellular Vesicles in Inflammatory Bowel Disease: Small Particles, Big Players. J Crohns Colitis 2021;15:499-510. [PMID: 32905585 DOI: 10.1093/ecco-jcc/jjaa179] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
5 Abakkouy Y, Cleynen I. The Promise of Polygenic Risk Scores as a Research Tool to Analyse the Genetics Underlying IBD Phenotypes. J Crohns Colitis 2021;15:877-8. [PMID: 33755717 DOI: 10.1093/ecco-jcc/jjab021] [Reference Citation Analysis]
6 Shi L, Han X, Li JX, Liao YT, Kou FS, Wang ZB, Shi R, Zhao XJ, Sun ZM, Hao Y. Identification of differentially expressed genes in ulcerative colitis and verification in a colitis mouse model by bioinformatics analyses. World J Gastroenterol 2020; 26(39): 5983-5996 [PMID: 33132649 DOI: 10.3748/wjg.v26.i39.5983] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
7 Vatn SS, Lindstrøm JC, Moen AE, Brackmann S, Tannæs TM, Olbjørn C, Bergemalm D, Keita ÅV, Gomollon F, Detlie TE, Lüders T, Kalla R, Adams A, Satsangi J, Jahnsen J, Vatn MH, Halfvarson J, Ricanek P, Nilsen H. Mucosal Gene Transcript Signatures in Treatment Naïve Inflammatory Bowel Disease: A Comparative Analysis of Disease to Symptomatic and Healthy Controls in the European IBD-Character Cohort. CEG 2022;Volume 15:5-25. [DOI: 10.2147/ceg.s343468] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Sun Y, Zhang Z, Zheng CQ, Sang LX. Mucosal lesions of the upper gastrointestinal tract in patients with ulcerative colitis: A review. World J Gastroenterol 2021; 27(22): 2963-2978 [PMID: 34168401 DOI: 10.3748/wjg.v27.i22.2963] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
9 van Hoeve K, Seyed Tabib NS, Dreesen E, Tops S, Hoffman I, Gils A, Ferrante M, Vermeire S. Infliximab Concentrations during Induction Are Predictive for Endoscopic Remission in Pediatric Patients with Inflammatory Bowel Disease under Combination Therapy. J Pediatr 2022;240:150-157.e4. [PMID: 34481805 DOI: 10.1016/j.jpeds.2021.08.079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Fiocchi C, Iliopoulos D. What's new in IBD therapy: An "omics network" approach. Pharmacol Res 2020;159:104886. [PMID: 32428668 DOI: 10.1016/j.phrs.2020.104886] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
11 Bravo F, Macpherson JA, Slack E, Patuto N, Cahenzli J, McCoy KD, Macpherson AJ, Juillerat P; SATICC (Sensitivity to Anti-TNF Inhibition in Crohn's disease and ulcerative Colitis) study group. Prospective Validation of CD-62L (L-Selectin) as Marker of Durable Response to Infliximab Treatment in Patients With Inflammatory Bowel Disease: A 5-Year Clinical Follow-up. Clin Transl Gastroenterol 2021;12:e00298. [PMID: 33735154 DOI: 10.14309/ctg.0000000000000298] [Reference Citation Analysis]
12 de-Madaria E, Mira JJ, Carrillo I, Afif W, Ang D, Antelo M, Bollipo S, Castells A, Chahal P, Heinrich H, Law JK, van Leerdam ME, Lens S, Pannala R, Park SH, Rabiee A, Savarino EV, Singh VK, Vargo J, Charabaty A, Drenth JPH. The present and future of gastroenterology and hepatology: an international SWOT analysis (the GASTROSWOT project). The Lancet Gastroenterology & Hepatology 2022;7:485-94. [DOI: 10.1016/s2468-1253(21)00442-8] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Costa-Santos MP, Frias-Gomes C, Oliveira A, Sabino J, Mañosa M, Ellul P, Sampaio A, Avedano L, Leone S, Colombel JF, Torres J. Conjugal inflammatory bowel disease: a systematic review and European survey. Ann Gastroenterol 2021;34:361-9. [PMID: 33948061 DOI: 10.20524/aog.2021.0598] [Reference Citation Analysis]
14 Chang JY, Cheon JH. Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review. Precis Future Med 2021;5:151-63. [DOI: 10.23838/pfm.2021.00128] [Reference Citation Analysis]
15 Porter RJ, Kalla R, Ho GT. Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Res 2020;9:F1000 Faculty Rev-294. [PMID: 32399194 DOI: 10.12688/f1000research.20805.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
16 Sandborn WJ, Armuzzi A, Liguori G, Irving PM, Sharara AI, Mundayat R, Lawendy N, Woolcott JC, Danese S. Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis. Inflamm Bowel Dis 2021:izab278. [PMID: 34958359 DOI: 10.1093/ibd/izab278] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]